Statement on COVID-19

23rd Mar 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need

First transdermal patch to treat schizophrenia hits market

18th Mar 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful

Richmond Pharmacology supporting clinical facilities in Nicaragua

30th Jan 2020

Richmond Pharmacology have developed a resourceful way to use study equipment to help reduce waste produced on site and support clinical facilities in under developed nations.

Charitable Contributions in 2019

02nd Jan 2020

As the 2019 year comes to an end, we would like to recognize the substantial charitable contributions made by the Richmond Pharmacology team; including our staff, academic

Richmond Pharmacology to provide Immediate Life Support (ILS) Courses

31st Jul 2019

In line with our on-going commitment to providing quality training and promoting the highest safety standard, Richmond Pharmacology are pleased to announce that our ILS

Echocardiography Course undertaken at Richmond Pharmacology

13th Mar 2019

Richmond Pharmacology CEO, Dr Jorg Taubel, Franklin Gordon, Resuscitation Simulation & Clinical Skills Practitioner and Dr Simon Coates, Research Physician respectively, all

Richmond Pharmacology, Medical Director, Dr Lorch welcomes new Clinical Pharmacology Apprentice scheme

06th Feb 2019

Significant work has been undertaken to push forward the launch of a new apprentice scheme aimed at raising the profile of this high-level occupation.

Dr Arezina article published in GMP review

16th Aug 2018

Richmond Pharmacology’s Research Director Dr Radivoj Arezina has written a piece for the July edition of GMP Review ‘ The application of GMP and its role in maximising the

Richmond Pharmacology Confirm event with the Department of International Trade

08th Aug 2018

Richmond Pharmacology is delighted to confirm an upcoming event alongside the Department of International Trade in the US. Early Phase Drug Development in the UK is to take

Click here to view our full news archive

Testimonials

I am very pleased with the Project Management of both studies undertaken on behalf of (blank) and any future studies we have to outsource will automatically be contracted to you.

- Anonymous

Many thanks for your time today, most impressed with the quality of the follow up to our enquiry.

- Anonymous

Please know that it has been an absolute pleasure collaborating with you and that I am most appreciative of the key contributions RPL has made to this project thus far. I hope I have the opportunity to work with RPL again in the very near future.

- Anonymous

Latest news

Statement on COVID-19

23rd Mar 2020

Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are

Read more ›

First transdermal patch to treat schizophrenia hits market

18th Mar 2020

The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia

Read more ›

Richmond Pharmacology supporting clinical facilities in Nicaragua

30th Jan 2020

Richmond Pharmacology have developed a resourceful way to use study equipment to help reduce waste produced on site

Read more ›

Cardiac Safety London

To help to enrich and speeding up your drug development programs, join us for a day of discovery as global experts

View event ›